NASDAQ: BCAXBicara Therapeutics Inc Stock
$11.49-0.32 (-2.71%)
Updated Jul 29, 2025
BCAX Price
$11.49
Fair Value Price
$8.98
Market Cap
$626.62M
52 Week Low
$7.80
52 Week High
$28.09
P/E
N/A
P/B
1.37x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
N/A
Beta
1.61
Next Earnings
Sep 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
BCAX Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BCAX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BCAX
Ranked#401 of 482
Ranked#401 of 482
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.18 | A | |
| $19.90 | A | |
| $49.29 | A |
Be the first to know about important BCAX news, forecast changes, insider trades & much more!
BCAX News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BCAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCAX ($11.49) is overvalued by 27.89% relative to our estimate of its Fair Value price of $8.98 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCAX ($11.49) is not significantly undervalued (27.89%) relative to our estimate of its Fair Value price of $8.98 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more BCAX due diligence checks available for Premium users.
Valuation
BCAX fair value
Fair Value of BCAX stock based on Discounted Cash Flow (DCF)
Price
$11.49
Fair Value
$8.98
Overvalued by
27.89%
BCAX ($11.49) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCAX ($11.49) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-195.28x
Market
31.93x
BCAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.37x
Industry
4.42x
BCAX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BCAX's financial health
Profit margin
Revenue
$0.0
Net Income
-$36.8M
Profit Margin
0%
Assets to liabilities
Assets
$478.1M
Liabilities
$19.1M
Debt to equity
0.04
BCAX's short-term assets ($470.75M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCAX's short-term assets ($470.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.1M
Investing
$0.0
Financing
$460.0k
BCAX vs Biotech Stocks
Bicara Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.